- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00078598
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
A total of 506 patients, 253 per arm, will be enrolled at 30 to 40 sites in the United States and Europe.
Patients will be randomly assigned to one of two treatment arms. In Arm A, patients will receive 375 mg/m2 of rituximab (US, Canada - Rituxan®; EU - Mabthera®), given as an IV infusion once weekly for 4 weeks. In Arm B, patients will receive Iodine I 131 Tositumomab therapy. For Arm B, patients undergo a two-phase treatment. In the first phase, termed the "dosimetric dose," patients will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of Tositumomab (35 mg) that has been labeled with 5 mCi (0.18 GBq) of iodine 131. Whole body gamma camera scans will be obtained three times (Day 0, Day 2, 3, or 4, and Day 6 or 7) following the dosimetric dose. Using the dosimetric data from these three imaging timepoints, the patient's weight, and platelet count, a patient-specific administered activity of iodine I 131 Tositumomab (expressed in mCi or GBq) will be calculated to deliver the desired total body dose of radiation (65 or 75 cGy). In the second phase, termed the "therapeutic dose," patients in Arm B will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient-specific administered activity of Iodine 131-conjugated Tositumomab (35 mg).
Patients on study will be followed for response and safety at Week 7, Week 13, and every 3 months for the first and second years, every 6 months for the third year, and then annually for the fourth and fifth years. Patients will be followed for safety only annually for years 6-10.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Northside Hospital
-
Contact:
- Barry Boatman, RN
- Phone Number: 404-303-3355
- Email: barry.boatman@northside.com
-
Principal Investigator:
- Ronald Steis, MD
-
-
Ohio
-
Dayton, Ohio, United States, 45409
- Not yet recruiting
- Medical Oncology/Hematology Associates
-
Contact:
- Cathy Hull, RN
- Phone Number: 937-223-2183
-
Principal Investigator:
- Basel Yanes, MD
-
-
Washington
-
Tacoma, Washington, United States, 98431
- Not yet recruiting
- Madigan Army Medical Center
-
Contact:
- Carol Dean, RN
- Phone Number: 253-968-3681
- Email: carol.ford@nw.amedd.army.mil
-
Principal Investigator:
- David E McCune, MD, MPH
-
Walla Walla, Washington, United States, 99362
- Recruiting
- St Mary Medical Center/Regional Cancer Center
-
Contact:
- Cathy McCauley, RN
- Phone Number: 509-522-5993
- Email: mccaca@smmc.com
-
Principal Investigator:
- Matthew Sacks, MD
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Not yet recruiting
- West Virginia University/Mary Babb Randolph Cancer Center
-
Contact:
- Robin Weisenborn, MT, CCRC
- Phone Number: 304-293-3709
- Email: WeisenbornR@rcbhsc.wvu.edu
-
Principal Investigator:
- Solveig Ericson, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- A histologically confirmed diagnosis of follicular lymphoma, Grade I, II, or III (WHO/REAL Classification) (follicular, small cleaved; follicular, mixed small-cleaved and large-cell; or follicular large-cell lymphoma in the International Working Formulation).
- Recurrent lymphoma after one or two qualifying therapy regimen(s).
- A performance status of at least 70% on the Karnofsky Scale.
- An absolute neutrophil count > 1500 cells/mm3 and a platelet count > 100,000 cells/mm3.
- Adequate renal function and adequate hepatic function.
- Bi-dimensionally measurable disease with at least one lesion measuring > or equal to 2.0 x 2.0 cm (i.e., > 4.0 cm2) by CT scan.
- HAMA negative.
- At least 18 years of age.
- Give written informed consent by signing an IRB/ethics committee approved informed consent form prior to study entry.
Exclusion Criteria
- Histological transformation to diffuse,large cell lymphoma
- More than 1 course of rituximab
- Disease better treated with limited field therapy
- Involvement of >25% of the intratrabecular marrow
- Active infection
- Significant cardiac disease
- Prior ChemoRx, biological therapy, radiation Rx, or high dose systemic steroid therapy within 8 weeks
- Prior radioimmunotherapy
- History of another malignancy
- HBsAg positivity
- CNS involvement with lymphoma
- Pregnant or nursing
- Ascites by physical exam
- Previous use of non-human monoclonal antibody therapy, known hypersensitive to murine proteins
- Hydronephrosis
- Radiotherapy to >25% of the blood forming marrow
- Prior stem cell transplant
- Failed stem cell harvest
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
- Tositumomab I-131
Other Study ID Numbers
- CCBX001-049
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Clinical Trials on Rituximab or Iodine I 131 Tositumomab Therapy
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedLymphoma, Non-HodgkinUnited States, France, United Kingdom
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
University of Michigan Rogel Cancer CenterGlaxoSmithKlineActive, not recruitingMultiple MyelomaUnited States
-
University of NebraskaNational Cancer Institute (NCI); Coulter Pharmaceutical, Inc.Terminated
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | Lymphoid Leukemia in RemissionUnited States
-
GlaxoSmithKlineCompletedNon-Hodgkin's LymphomaUnited States
-
GlaxoSmithKlineWithdrawnLymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, FollicularUnited States